Graham Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Graham Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$416K	Buy	+24,035	New	+$329K	0.01%	778
2026 Q1	–	Sell	-90,424	Closed	-$1.14M	–	1142
2025 Q4	$1.14M	Buy	+90,424	New	+$1.03M	0.03%	361
2025 Q3	–	Sell	-25,681	Closed	-$208K	–	1231
2025 Q2	$208K	Buy	+25,681	New	+$194K	﹤0.01%	1121
2024 Q1	–	Sell	-22,066	Closed	-$134K	–	1049
2023 Q4	$134K	Buy	+22,066	New	+$98.3K	﹤0.01%	891
2023 Q3	–	Sell	-30,092	Closed	-$93.3K	–	1001
2023 Q2	$93.3K	Buy	30,092 +9,046	+43%	+$19.3K	﹤0.01%	894
2023 Q1	$29.3K	Sell	21,046 -513,783	-96%	-$1.02M	﹤0.01%	1013
2022 Q4	$1.06M	Buy	+534,829	New	+$1.2M	0.03%	506
2022 Q2	–	Sell	-103,532	Closed	-$431K	–	989
2022 Q1	$431K	Buy	+103,532	New	+$458K	0.01%	604

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Graham Capital Management's AMRX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 24,035 shares worth $416K. The stake represents 0.01% of the portfolio and ranks #778 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in AMRX as recently as Q4 2025.

Graham Capital Management first reported a position in AMRX in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.14M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Graham Capital Management held 24,035 shares of Amneal Pharmaceuticals worth $416K as of Q2 2026.
Amneal Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
Amneal Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #778 holding.
Graham Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
Graham Capital Management's Amneal Pharmaceuticals position peaked at $1.14M in Q4 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.